EWTX
Edgewise Therapeutics, Inc.
$35.32
-0.73%
2026-05-08
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Key Fundamentals
Forward P/E
-14.68
EPS (TTM)
$-1.66
ROE
-38.1%
Profit Margin
0.0%
Debt/Equity
0.77
Price/Book
7.22
Beta
0.28
Market Cap
$3.82B
Avg Volume (10D)
1.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$39.96
60D Low
$26.82
Avg Volume
939K
Latest Close
$35.32
Get breakout alerts for EWTX
Sign up for Breakout Scanner to receive daily notifications when EWTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Edgewise Therapeutics, Inc. (EWTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors EWTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. EWTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.